|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **L858R**  **(n=59)** | **Exon 19 Deletion**  **(n=94)** | **Never Smoker**  **(n=95)** | **Ever Smokers**  **(n=58)** |
| **Median age (range)** | 64 (39-89) | 64 (29-87) | 64 (35-87) | 64 (24-89) |
| **Sex**  **Female**  **Male** | 38 (64%)  21 | 63 (67%)  31 | 63 (66%)  32 | 38 (65%)  20 |
| **Smoking status**  **Never**  **Ever** | 33 (56%)  26 | 62 (66%)  32 | NA | NA |
| **Year EGFR-TKI Start**  **2014 and earlier**  **2015**  **2016 - ongoing** | 19 (32%)  20 (34%)  20 | 17 (18%)  35 (37%)  42 | 22 (23%)  37 (39%)  36 | 14 (24%)  18 (31%)  26 |
| **EGFR-TKI used**  **Erlotinib**  **Gefitinib**  **Afatanib** | 55 (93%)  -  4 | 86 (91%)  1  7 | 88 (93%)  1  6 | 53 (91%)  -  5 |
| **Median TMB (range)** | 4.72 (0.82-17.92) | 3.17 (0.94-10.20) | 3.77 (0.82-10.66) | 4.09 (0.94-17.92) |